Inspire Pharmaceuticals, Inc. announced a licensing agreement with Kirin Brewery Co., Ltd., of Tokyo, Japan, in which Kirin’s Pharmaceutical Division has obtained rights to develop and commercialise Inspire’s lung-disease diagnostic adjunct product, INS316 Diagnostic, in twenty- one Asian countries and regions including Japan. The initial indication for INS316 will be to aid in the diagnosis Read more about Inspire And Kirin Enter Diagnostics Collaboration[…]